BMS 986178

Drug Profile

BMS 986178

Alternative Names: BMS-986178

Latest Information Update: 21 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; National Cancer Institute (USA); Stanford University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I B cell lymphoma

Most Recent Events

  • 09 Apr 2018 Phase-I clinical trials in B-cell lymphoma (Early-stage disease, Combination therapy, Second-line therapy or greater) in USA (Intratumoural) (NCT03410901)
  • 25 Jan 2018 National Cancer Institute plans a phase I trial for Non-Hodgkin Lymphoma (Combination therapy, Newly diagnosed, Second-line therapy or greater) in USA , (NCT03410901)
  • 01 Jun 2016 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease, Recurrent, Monotherapy, Combination therapy) in USA (unspecified route) (NCT02737475)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top